Hemolytic uremic syndrome following Campath-1H induction
Open Access
- 12 January 2007
- journal article
- case report
- Published by Frontiers Media SA in Transplant International
- Vol. 20 (4), 386-389
- https://doi.org/10.1111/j.1432-2277.2006.00445.x
Abstract
Hemolytic uremic syndrome (HUS) is a rare complication following solid organ transplantation. We report on a patient who underwent renal transplantation using Campath‐1H induction and tacrolimus maintenance therapy who developed HUS, which was managed by plasma exchange and switch to Rapamycin. However, graft function could not be restored.Keywords
This publication has 19 references indexed in Scilit:
- Campath and renal transplant rejectionClinical Transplantation, 2004
- Campath-1H in renal transplantation: The University of Wisconsin experienceSurgery, 2004
- Antibody Therapy in the Management of Shiga Toxin-Induced Hemolytic Uremic SyndromeClinical Microbiology Reviews, 2004
- Atypical relapse of hemolytic uremic syndrome after transplantationPediatric Nephrology, 2004
- Steroid- and ATG-Resistant Rejection After Double Forearm Transplantation Responds to Campath-1HAmerican Journal of Transplantation, 2004
- Attempted treatment of factor H deficiency by liver transplantationPediatric Nephrology, 2004
- RESULTS FROM A HUMAN RENAL ALLOGRAFT TOLERANCE TRIAL EVALUATING THE HUMANIZED CD52-SPECIFIC MONOCLONAL ANTIBODY ALEMTUZUMAB (CAMPATH-1H)Transplantation, 2003
- Hemolytic-uremic syndrome in association with both cyclosporine and tacrolimusTransplant International, 2000
- POSTTRANSPLANT HEMOLYTIC UREMIC SYNDROME IN ADULT RETRANSPLANTED KIDNEY GRAFT RECIPIENTS: ADVANTAGE OF FK506 THERAPY?Transplantation, 1998
- Inhaled nitric oxide and heparin for infantile primary pulmonary hypertensionThe Lancet, 1998